Relationship of Serum Adiponectin Levels and Metformin Therapy in Patients with Type 2 Diabetes

Hormone and Metabolic Research

Volumn 48, Issue 2, 2016, Pages 92-98

  Su, J R ^a   Lu, Z H ^a   Su, Y ^b   Zhao, N ^b   Dong, C L ^a   Sun, L ^a   Zhao, S F ^a   Li, Y ^a  

^a LINYI PEOPLE'S HOSPITAL   (China)

^b Yishui Central Hospital   (China)

Author keywords

antidiabetic drugs; cohort study; efficacy; meta analysis; post treatment

Indexed keywords

ADIPONECTIN; METFORMIN; ADIPOQ PROTEIN, HUMAN;

ARTICLE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; BLOOD; DIABETES MELLITUS, TYPE 2;

ADIPONECTIN; DIABETES MELLITUS, TYPE 2; HUMANS; METFORMIN;

EID: 84955567715     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0035-1569287     Document Type: Article

References (45)

1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care: 2006; 29 01 S43 S48
2. Idf Diabetes Atlas G. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013. Diabetes Res Clin Pract. 2015; 109 461 465
3. Guariguata L. Contribute data to the 6th edition of the IDF Diabetes Atlas. Diabetes Res Clin Pract: 2013; 100 280 281
4. Nathan D. M., Buse J. B., Davidson M. B., Ferrannini E., Holman R. R., Sherwin R., Zinman B. American Diabetes A, European Association for Study of D. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care: 2009; 32 193 203
5. Scarpello J. H., Howlett H. C. Metformin therapy and clinical uses. Diab Vasc Dis Res: 2008; 5 157 167
6. Lehman D. M., Lorenzo C., Hernandez J., Wang C. P. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care: 2012; 35 1002 1007
7. Fox M. M., Phoenix K. N., Kopsiaftis S. G., Claffey K. P. AMP-Activated Protein Kinase alpha 2 Isoform Suppression in Primary Breast Cancer Alters AMPK Growth Control and Apoptotic Signaling. Genes Cancer: 2013; 4 3 14
8. Boyle J. G., Logan P. J., Jones G. C., Small M., Sattar N., Connell J. M., Cleland S. J., Salt I. P. AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia: 2011; 54 1799 1809
9. Doogue M. P., Begg E. J., Moore M. P., Lunt H., Pemberton C. J., Zhang M. Metformin increases plasma ghrelin in Type 2 diabetes. Br J Clin Pharmacol: 2009; 68 875 882
10. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev: 2005; 26 439 451
11. Chandran M., Phillips S. A., Ciaraldi T., Henry R. R. Adiponectin: more than just another fat cell hormone? Diabetes Care: 2003; 26 2442 2450
12. Diez J. J., Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol: 2003; 148 293 300
13. Xu A., Chan K. W., Hoo R. L., Wang Y., Tan K. C., Zhang J., Chen B., Lam M. C., Tse C., Cooper G. J., Lam K. S. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem: 2005; 280 18073 18080
14. Jalovaara K., Santaniemi M., Timonen M., Jokelainen J., Kesaniemi Y. A., Ukkola O., Keinanen-Kiukaanniemi S., Rajala U. Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population. Metabolism: 2008; 57 1130 1134
15. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M. L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med: 2001; 7 941 946
16. Berg A. H., Combs T. P., Du X., Brownlee M., Scherer P. E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med: 2001; 7 947 953
17. Zulian A., Cancello R., Girola A., Gilardini L., Alberti L., Croci M., Micheletto G., Danelli P., Invitti C. In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obes Facts: 2011; 4 27 33
18. Tamura Y., Watada H., Sato F., Kumashiro N., Sakurai Y., Hirose T., Tanaka Y., Kawamori R. Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. Diabetes Obes Metab: 2008; 10 733 738
19. Esteghamati A., Mousavizadeh M., Noshad S., Zandieh A., Zarei H., Nakhjavani M. Gender-dependent effects of metformin on vaspin and adiponectin in type 2 diabetes patients: a randomized clinical trial. Horm Metab Res: 2013; 45 319 325
20. Miazgowski T., Dziwura-Ogonowska J., Safranow K., Iskierska K., Widecka K. Changes in adiponectin level and fat distribution in patients with type 2 diabetes. Eur J Clin Invest: 2014; 44 192 199
21. Hanefeld M., Pfutzner A., Forst T., Kleine I., Fuchs W. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol: 2011; 10 65
22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol: 2010; 25 603 605
23. Zintzaras E., Ioannidis J. P. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol: 2005; 28 123 137
24. Peters J. L., Sutton A. J., Jones D. R., Abrams K. R., Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA: 2006; 295 676 680
25. Zintzaras E., Ioannidis J. P. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics: 2005; 21 3672 3673
26. Jung H. S., Youn B. S., Cho Y. M., Yu K. Y., Park H. J., Shin C. S., Kim S. Y., Lee H. K., Park K. S. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism: 2005; 54 314 320
27. Araki T., Emoto M., Teramura M., Yokoyama H., Mori K., Hatsuda S., Maeno T., Shinohara K., Koyama H., Shoji T., Inaba M., Nishizawa Y. Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. Metabolism: 2006; 55 996 1001
28. Derosa G., Salvadeo S. A., D'Angelo A., Fogari E., Ragonesi P. D., Ciccarelli L., Piccinni M. N., Ferrari I., Gravina A., Maffioli P., Cicero A. F. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Arch Med Res: 2008; 39 412 419
29. Erdem G., Dogru T., Tasci I., Bozoglu E., Muhsiroglu O., Tapan S., Ercin C. N., Sonmez A. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract: 2008; 82 214 218
30. Eriksson A., Attvall S., Bonnier M., Eriksson J. W., Rosander B., Karlsson F. A. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab: 2007; 9 483 489
31. Fan H., Pan Q., Xu Y., Yang X. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metabol: 2013; 57 702 708
32. Goldberg R., Temprosa M., Otvos J., Brunzell J., Marcovina S., Mather K., Arakaki R., Watson K., Horton E., Barrett-Connor E. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab: 2013; 98 3989 3998
33. Kadoglou N. P., Kapelouzou A., Tsanikidis H., Vitta I., Liapis C. D., Sailer N. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naive patients with type 2 diabetes. Exp Clin Endocrinol Diabetes: 2011; 119 63 68
34. Kim H. J., Kang E. S., Kim D. J., Kim S. H., Ahn C. W., Cha B. S., Nam M., Chung C. H., Lee K. W., Nam C. M., Lee H. C. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf): 2007; 66 282 289
35. Miazgowski T., Dziwura-Ogonowska J., Safranow K., Iskierska K., Widecka K. Changes in adiponectin level and fat distribution in patients with type 2 diabetes. Eur J Clin Invest: 2014; 44 192 199
36. Ohira M., Miyashita Y., Ebisuno M., Saiki A., Endo K., Koide N., Oyama T., Murano T., Watanabe H., Shirai K. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res Clin Pract: 2007; 78 34 41
37. Putz D. M., Goldner W. S., Bar R. S., Haynes W. G., Sivitz W. I. Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism: 2004; 53 1454 1461
38. Sharma P. K., Bhansali A., Sialy R., Malhotra S., Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf): 2006; 65 722 728
39. Teranishi T., Ohara T., Maeda K., Zenibayashi M., Kouyama K., Hirota Y., Kawamitsu H., Fujii M., Sugimura K., Kasuga M. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism: 2007; 56 1418 1424
40. Tiikkainen M., Hakkinen A. M., Korsheninnikova E., Nyman T., Makimattila S., Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes: 2004; 53 2169 2176
41. Wang H., Ni Y., Yang S., Li H., Li X., Feng B. The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus. Curr Ther Res Clin Exp: 2013; 75 88 92
42. Shin L., Bregman H., Breeze J. L., Noyes N., Frazier J. A. Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol: 2009; 19 275 279
43. Diabetes Prevention Program Research G Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care: 2012; 35 731 737
44. Kirino Y., Sei M., Kawazoe K., Minakuchi K., Sato Y. Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocr J: 2012; 59 949 953
45. Singh S., Akhtar N., Ahmad J. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study. Diabetes Metab Syndr: 2012; 6 207 211